ValiRx plc (AIM:VAL)

Market Cap	1.68M
Revenue (ttm)	49.78K
Net Income (ttm)	-1.92M
Shares Out	374.35M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,102,857
Average Volume	1,502,684
Open	0.4850
Previous Close	0.4500
Day's Range	0.4300 - 0.4850
52-Week Range	0.3750 - 3.5000
Beta	-0.47
RSI	42.19
Earnings Date	May 28, 2025

About ValiRx

ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer. It also develops VAL301, a peptide ingredient that in pre-clinical development for the treatment of endometriosis; BC201,...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 16
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: VAL

Financial Performance

In 2024, ValiRx's revenue was 49,775, an increase of 418.49% compared to the previous year's 9,600. Losses were -1.92 million, -5.99% less than in 2023.